Operating Leverage Inflection
Expected: Q3 FY26HIGH confidence
What: EBITDA Margin: 35.4%
Impact: 820 bps expansion
Pfizer Ltd: Stock Analysis & Fundamentals
Updated this weekPfizer Ltd (Pharma - MNC bulk Drugs) — fundamental analysis, earnings data, and key metrics. PE: 27.2. ROE: 18.0%. This stock is not currently in the Nifty 500 momentum outperformers list.
Pfizer Ltd Key Facts
What's Happening
💪Debt reduced 39% YoY — balance sheet strengthening
🌐FII stake decreased 0.9% this quarter
🏛️DII accumulation — stake up 1.1%
Earnings Acceleration Triggers
1. Operating Leverage Inflection
Q3 FY26HIGH
2. New Product Or Brand Launch
Short termMEDIUM
Key Risks
1. Loss of exclusivity (LOE) and patent cliffs for major drugs like Eliquis and Ibr
HIGH2. GST tax demands and antitrust settlements
MEDIUMSector-Specific Signals
Eliquis Growth22%22%
Mucaine Growth14%14%
Manufacturing Capacity3.6 billion
Phase 3 Pipeline Assets30
Key Numbers
Current Price
₹4,507
Dividend Yield
1.66%
Market Cap
20.6K Cr
Valuation
N/AWhy Are Pfizer Ltd's Earnings Accelerating?
Based on Q3 FY26 (web) earnings • Updated Apr 19, 2026
New Product Or Brand Launch
Expected: Short termMEDIUM confidence
What: Pipeline Assets: Prevenar 20
Impact: Not Given
What Are the Key Risks for Pfizer Ltd?
Earnings deceleration risks from management commentary
Loss of exclusivity (LOE) and patent cliffs for major drugs like Eliquis and Ibr
HIGHTrigger: Loss of exclusivity (LOE) and patent cliffs for major drugs like Eliquis and Ibrance.
Impact: PAT impact: $1.5 billion revenue hit
Management view: Cost-cutting and pipeline investment
Monitor: regulatory
GST tax demands and antitrust settlements
MEDIUMTrigger: GST tax demands and antitrust settlements.
Impact: PAT impact: ₹29.48 lakh GST demand
Management view: Plans to appeal
Monitor: litigation
What Did Pfizer Ltd Report This Quarter?
Headline numbers from the latest earnings call
Revenue
₹645.03 crore
YoY +19.9%QoQ -0.14%
Revenue growth was driven by core therapeutic segments and power brands like Mucaine and Eliquis.
EBITDA
₹228.3 crore
YoY +55.8%Margin 35.4%
EBITDA expansion of 820 basis points was aided by effective cost management and a favorable product mix.
PAT
₹141.84 crore
YoY +11.1%QoQ -24.96%
Net profit growth was moderated by exceptional items of ₹58.20 crore related to a Cipla partnership and labor law changes.
Other Highlights
• Exceptional items of ₹58.20 crore recognized for Q3 FY26.
• Total income for the quarter reached ₹683.24 crore.
• Earnings per share grew to ₹31.01 from ₹27.89 YoY.
What Sector Metrics Matter for Pfizer Ltd?
Sub-sector-specific signals from the latest concall — each with management's stated reason for the change
Eliquis Growth
22%
YoY 22%
Why: Strong performance in the CVS segment as per IQVIA data.
Mucaine Growth
14%
YoY 14%
Why: Steady demand in the antacid category.
Manufacturing Capacity
3.6 billion
Why: Stable run rate at the Goa facility.
Phase 3 Pipeline Assets
30
Why: Reflects global R&D focus on oncology and innovative medicines.
What Is Pfizer Ltd's Management Guidance?
Forward-looking targets from management for FY26
OPM Guidance
27.8%
Revenue Outlook
$59.5 to $62.5 Billion (Global)
Margin Outlook
Anticipated stable gross and operating margins
Capex Plan
$10.5 to $11.5 Billion
R&D Expenses
Volume
Operational revenue growth excluding COVID and LOE
Management Tone: CAUTIOUS
Guidance Changes
LOWERED
Revenue: $61.0 – $64.0 billion → Approximately $62.0 billion
Lower COVID vaccine sales and patent expirations
The above analysis is parsed from publicly available earnings call transcripts. This is educational research only — not investment advice. Last updated Apr 19, 2026.
Other Top Pharma - MNC bulk Drugs Stocks Beating Nifty 500
Frequently Asked Questions: Pfizer Ltd
Based on publicly available financial data. This is educational research, not investment advice.
What were Pfizer Ltd's latest quarterly results?
Pfizer Ltd's latest quarterly results (Mar 2026) show
- PAT Growth YoY: -39.6%
- Revenue Growth YoY: +6.3%
- Operating Margin: 38.0%
What is Pfizer Ltd's current PE ratio?
Pfizer Ltd's current PE ratio is 27.2x.
- Current PE: 27.2x
- Market Cap: 20.6K Cr
- Dividend Yield: 1.66%
What is Pfizer Ltd's price-to-book ratio?
Pfizer Ltd's price-to-book ratio is 4.9x.
- Price-to-Book (P/B): 4.9x
- Book Value per Share: ₹919
- Current Price: ₹4507
Is Pfizer Ltd a fundamentally strong company?
Pfizer Ltd's fundamental strength based on key financial ratios
- Return on Capital (ROCE): 24.0%
Is Pfizer Ltd debt free?
Pfizer Ltd has a debt-to-equity ratio of N/A.
- Total Debt: ₹70 Cr
What is Pfizer Ltd's return on equity (ROE) and ROCE?
Pfizer Ltd's return ratios over recent years
- FY2024: ROCE 22.0%
- FY2025: ROCE 22.0%
- FY2026: ROCE 24.0%
Is Pfizer Ltd's cash flow positive?
Pfizer Ltd's operating cash flow is positive (FY2026).
- Cash from Operations (CFO): ₹968 Cr
- Free Cash Flow (FCF): ₹406 Cr
- CFO/PAT Ratio: 134% (strong cash conversion)
What is Pfizer Ltd's dividend yield?
Pfizer Ltd's current dividend yield is 1.66%.
- Dividend Yield: 1.66%
- Current Price: ₹4507
Who holds Pfizer Ltd shares — promoters, FII, DII?
Pfizer Ltd's shareholding pattern (Mar 2026)
- Promoters: 63.9%
- FII (Foreign): 2.8%
- DII (Domestic): 16.9%
- Public: 16.4%
Is promoter holding increasing or decreasing in Pfizer Ltd?
Pfizer Ltd's promoter holding has remained stable recently.
- Current Promoter Holding: 63.9% (Mar 2026)
- Previous Quarter: 63.9% (Dec 2025)
- Change: 0.00% (stable)
Is Pfizer Ltd a new momentum entry or an established outperformer?
Pfizer Ltd is an established outperformer with 1 weeks of consecutive Nifty 500 outperformance.
What are the growth catalysts for Pfizer Ltd?
Pfizer Ltd has 2 key growth catalysts identified from recent earnings analysis
- Operating Leverage Inflection — Significant margin expansion despite moderate PAT growth.
- New Product Or Brand Launch — New launches are critical to offset the patent cliff of older blockbusters.
What are the key risks in Pfizer Ltd?
Pfizer Ltd has 2 key risks worth monitoring
- [HIGH] Loss of exclusivity (LOE) and patent cliffs for major drugs like Eliquis and Ibr — Loss of exclusivity (LOE) and patent cliffs for major drugs like Eliquis and Ibrance.
- [MEDIUM] GST tax demands and antitrust settlements — GST tax demands and antitrust settlements.
What is Pfizer Ltd's management guidance for growth?
Pfizer Ltd's management has provided the following forward guidance for FY26
- Revenue outlook: $59.5 to $62.5 Billion (Global)
- OPM guidance: 27.8%
- Capex plan: $10.5 to $11.5 Billion for R&D Expenses
- Management tone: cautious
- Milestone: [LOWERED] Revenue: $61.0 – $64.0 billion → Approximately $62.0 billion
What sector-specific metrics matter most for Pfizer Ltd?
Pfizer Ltd's most important sub-sector-specific KPIs from the latest concall
- Eliquis Growth: 22% (YoY 22%) — Strong performance in the CVS segment as per IQVIA data.
- Mucaine Growth: 14% (YoY 14%) — Steady demand in the antacid category.
- Manufacturing Capacity: 3.6 billion — Stable run rate at the Goa facility.
- Phase 3 Pipeline Assets: 30 — Reflects global R&D focus on oncology and innovative medicines.
Is Pfizer Ltd worth studying for long term investment?
Based on quantitative research signals, here is why Pfizer Ltd may be worth studying
- Cash flow is positive — CFO ₹968 Cr
What is the investment thesis for Pfizer Ltd?
Pfizer Ltd investment thesis summary:
Research Signals (Bull Case)
- Growth catalyst: Operating Leverage Inflection
Risk Factors (Bear Case)
- Key risk: Loss of exclusivity (LOE) and patent cliffs for major drugs like Eliquis and Ibr
What is the future outlook for Pfizer Ltd?
Pfizer Ltd's forward outlook based on current data signals
- Key Catalyst: Operating Leverage Inflection
- Key Risk: Loss of exclusivity (LOE) and patent cliffs for major drugs like Eliquis and Ibr
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.